# David Sidransky

> David Sidransky is a Series B investor at Advaxis backing Health Care and Biotechnology. See 3 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Advaxis](https://shizune.co/investors/profile/advaxis-inc)
- Total investments: 3
- Last investment: Dec 2020
- Lead investor: 100%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/david-sidransky-0095253

David Sidransky is a Series B investor at Advaxis focused on Health Care and Biotechnology. Dr. Sidransky is a renowned oncologist and research scientist named and profiled by TIME magazine in 2001 as one of the top physicians and scientists in America, recognized for his work with early detection of cancer. Since 1994, Dr. Sidransky has been the Director of the Head and Neck Cancer Research Division and Professor of Oncology,Otolaryngology, Genetics, and Pathology at Johns Hopkins University School of Medicine. He has served as Chairman of the Board of Directors of Champions Oncology since October 2007 and was, until the merger with Eli Lilly, a director and Vice-Chairman of ImClone Systems, Inc. He is the Chairman of Tamir Biotechnology and serves on the Board of Directors of Rosetta Genomics, Immune Pharmaceuticals, and Celsus. He is serving and has served on scientific advisory boards of MedImmune, Roche, Amgen, and Veridex, LLC (a Johnson & Johnson diagnostic company), among others. Dr. Sidransky served as Director (2005-2008) of the American Association for Cancer Research (AACR).

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 2 | 67% |
| Biotechnology | 2 | 67% |
| Pharmaceutical | 2 | 67% |
| Therapeutics | 1 | 33% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 1 | 33% |
| Series C | 1 | 33% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| BioSight | BioSight is a biopharmaceutical private company founded in 2000 and re launched in mid 2009, revolutionizing the research and development of innovative cancer targeted pro-drugs. BioSight has developed technology S2DOT TM and a pipeline of targeted pro-drugs, that can target and release chemotherapy drugs inside cancer cells, while significantlyminimizing the systemic toxicity associated with conventional chemotherapy ​​treatments.​​​ | $27M | Series C | Dec 02, 2020 |  |
| BioSight | BioSight is a biopharmaceutical private company founded in 2000 and re launched in mid 2009, revolutionizing the research and development of innovative cancer targeted pro-drugs. BioSight has developed technology S2DOT TM and a pipeline of targeted pro-drugs, that can target and release chemotherapy drugs inside cancer cells, while significantlyminimizing the systemic toxicity associated with conventional chemotherapy ​​treatments.​​​ | $19M | Series C | Mar 11, 2020 |  |
| Biond Biologics | Biond Biologics is a discovery and development company in the prosperous and evolving field of cancer immunotherapy and autoimmune disorders. Biond aims to translate high quality science into breakthrough therapies that will address unmet medical needs while focusing on innovative drugs. Biond is an Israeli company located at Galilee region,combining excellent science and out of the box innovation. | $17M | Series B | Jan 08, 2019 |  |

3 of 3 investments shown.

## Co-investors
- [Arkin Bio Ventures](https://shizune.co/investors/profile/arkin-bio-ventures) — VC Fund, 2 deals together
- [SBI Japan-Israel Innovation Fund](https://shizune.co/investors/profile/sbi-japan-israel-innovation-fund) — VC Fund, 2 deals together
- [Biotel](https://shizune.co/investors/profile/biotel) — VC Fund, 1 deal together
- [Celgene](https://shizune.co/investors/profile/celgene) — VC Fund, 1 deal together
- [Harel Insurance and Financial](https://shizune.co/investors/profile/harel-insurance-investments-and-financial-services) — VC Fund, 1 deal together
- [Migdal Insurance and Financial Holdings](https://shizune.co/investors/profile/migdal-insurance-and-financial-holdings-ltd) — VC Fund, 1 deal together

## About Advaxis

VC Fund · Princeton, United States

Advaxis is a clinical-stage biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. Advaxis immunotherapies are based on a novel platform technology using live, attenuated bacteria that are bio-engineered to secrete antigen/adjuvant fusion protein(s) designed to redirect the powerful immuneresponse all human beings have to the bacterium to the cancer itself.ADXS-HPV is being evaluated in four clinical trials for HPV-associated diseases: recurrent/refractory cervical cancer (India), locally advanced cervical cancer (GOG/NCI US study), head and neck cancer (CRUK study), and anal cancer (BrUOG). Over fifteen (15) distinct constructs are in various stages of development, developed directly by the Company and through strategic collaborations with recognized centers of excellence.

5 contacts available at Advaxis.

| Name | Title | Profile |
| --- | --- | --- |
| David Sidransky | Director | https://shizune.co/investors/profile/david-sidransky |
| Andres Gutierrez | Executive Vice President & Chief Medical Officer | https://shizune.co/investors/profile/andres-a-gutierrez |
| Chris French | Vice President and Executive Director, Medical Affairs | https://shizune.co/investors/profile/chris-french |
| Chris L. French | Vice President and Executive Director, Medical Affairs | https://shizune.co/investors/profile/chris-l-french-mba |
| Igor Gitelman | Vice President Finance | https://shizune.co/investors/profile/igor-gitelman |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does David Sidransky invest in?

David Sidransky invests primarily in Health Care, Biotechnology and Pharmaceutical startups, most often at Series B and Series C stage. Most of the 3 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did David Sidransky last invest?

The most recent investment recorded for David Sidransky closed in Dec 2020. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co